On August 7, the National Health Insurance Bureau officially publicized the list of medicines that passed the preliminary review for the 2024 adjustment of the health insurance catalog. A total of 626 declarations were received from enterprises, and 440 drugs passed the preliminary formal review.
Compared with 2023, the number of drugs declared and passed this year have both increased. A number of industry experts analyzed that the enthusiasm of enterprises to participate in this year's state talks is closely related to the recent introduction of a number of places to support the whole chain of innovative drug programs.
As early as March this year, the market has been rumored that the state will launch the “whole chain to support innovative drugs” policy news. July 5, the State Council executive meeting to formally consider the adoption of the relevant implementation plan. In the meantime, Beijing, Guangzhou, Zhuhai and other places have support documents issued.
At the end of July, as the national biopharmaceutical R & D and industrialization of the highland of Shanghai, the official launch of the “biopharmaceutical industry to support the whole chain of innovation and development of a number of opinions” (hereinafter referred to as “a number of opinions”), the content of the 8 links involving 37 specific measures, which is no lack of “real money” of financial support.
The above policy on the pharmaceutical secondary market has been boosted, but there are industry observers bluntly said, “the whole chain of support” involves incentives still can not make the current difficulties in financing China's innovative drugs really “get out of the woods”.
Why have Chinese biopharmaceutical companies been calling for “full chain support”? To what extent can the support policies introduced by different regions alleviate the operational pressure faced by innovative drug companies? “Medical Think Tank interviewed Jin Chunlin, director of Shanghai Health and Health Development Research Center.
MedJ Tank: Behind the industry's strong call for “full chain support”, what difficulties do China's pharmaceutical companies face?
JIN CHUNLIN: It mainly reflects the fact that the pharmaceutical industry is currently facing severe existential challenges. China's biomedical industry entered a rapid development stage around 2017 and reached its peak in 2021. Subsequently, due to changes in the economic, political and other external environment, biomedicine appeared “bubble” rupture, some people jokingly said that the biomedical industry has entered the winter period.
In the past two years, there are many domestic pharmaceutical companies sold their pipeline, the surface looks very lively, seems to be a strong proof of China's pharmaceutical R & D capabilities recognized by the world. However, there are a lot of necessity, enterprises know that the current is not a good time to sell, but in order to solve the financial difficulties, can only choose to sell. This is not a devastating blow to the industry as a whole, but some of the potential pipeline sold to foreign countries, domestic enterprises have lost the initiative to further explore and develop.
Innovative drug R&D is characterized by high investment, long cycle and high risk of failure. In the poor market environment, it is difficult for enterprises to recover on their own, and there is an urgent need for the government to introduce supportive policies with strength. Because drugs from R & D to commercialization, involving more than just the strength of a single sector, so companies are very eager to industry-wide, multi-sectoral support measures to give a strong stimulus.
MedJ : In the Several Opinions issued by Shanghai, it is mentioned that the maximum support for Class 1 new drugs with outputs of 10 million, 20 million and 30 million RMB will be given to the applicants registered in Shanghai who have carried out domestic Phase I, Phase II and Phase III clinical trials respectively. Some industry insiders said that innovative drugs have been said to have “10 years and 1 billion dollars investment”, according to which the subsidized funds are still “a drop in the bucket”, how do you think about this statement?
Jin Chunlin: “10 years and 1 billion dollars” is generally for the first-in-class, but unfortunately our country at present there is basically no such products. 10 million yuan of subsidies, if it is three years ago when the external funding environment is better, for the enterprise may not be very meaningful, but in the industry as a whole, the downturn of the current precious funds. But in the current downturn of the industry as a whole, these funds are invaluable. But what needs to be considered is, for the future development of the biomedical industry, whether the government should directly invest, or to create a favorable environment, in the long run, the latter is more significant.
MedJ The Opinions cover eight aspects: R&D, clinical trials, review and approval, marketing, industrialization, investment and financing, data resource utilization and internationalization. Which segment is our “weak point” in the past, or the dimension that the industry is most concerned about at present?
Jin Chunlin: The bursting of the bubble mainly points to the problem of investment and financing. After the deterioration of the external environment, VC and PE are not willing to invest in biopharmaceuticals. Biomedical industry chain is very long, only the R & D end involves a phase two phase three, after a period of investment, enterprises if the second phase can not raise enough funds, it means that the whole chain is broken, which is not the same as real estate buildings are not the same as the R & D funds are broken basically means that “all the previous work is lost”.
The situation on the listing side is also not optimistic, it has been nearly a year since any pharmaceutical company listed on the Shanghai and Shenzhen stock exchanges. The front-end can not raise money, the back-end can not be listed, “no money” has become the biggest problem for enterprises to survive. Therefore, the biggest role of the whole chain policy is to restore confidence in the biomedical industry, so that more market capital injection.
Another important aspect that enterprises are concerned about is the issue of medical insurance access and hospital access. State talks do give innovative drug companies a path to commercialization, but now the general feedback voice is that the rate of reduction is too large, 60% of the rate of reduction for a truly innovative drugs, it is difficult to make up for the huge investment in the R & D side, and can not incentivize real innovation, many drug companies are calling for the rate of reduction to be appropriately adjusted downward.
At present, some domestic self-developed drugs have even seen a 10-20 times price difference in the domestic and overseas markets, and some of them are underpriced in China. In my opinion, for first-in-class and best-in-class drugs, the criteria should be appropriately relaxed in health insurance pricing, and the price should not be endlessly lowered in contract renewal, but categorized according to the degree of innovation.
Of course, after health insurance access, hospital access is equally important, which means whether companies can get commercial returns. But how to get through the national drug landing “the last kilometer” is also the enterprise is currently facing the problem.
MedJ : On the issue of nationally-talked drugs landing in hospitals, some hospital health insurance offices said that under the incentive policy of the province's health insurance, hospitals may not lose money by using nationally-talked drugs, but if they don't use them, the hospitals' surplus may be even more, so what do you think should be done to get through the last kilometer?
Jin Chunlin: The local medical insurance bureau has no authority in terms of access to medical insurance, but it has authority in terms of access to hospitals, and Shanghai has done a better job in this regard. Several Opinions mentioned two “exceptions”: one is that when the medical insurance determines the total amount of hospital medical insurance, innovative drugs and innovative devices will be listed separately and will not be included in the total amount or the total budget; the second is that innovative drugs will not be included in the payment standard when the DRG/DIP payment is made. The two “exclusions” theoretically prevent the use of innovative drugs from affecting the settlement of hospital health insurance.
However, we also need to see that the actual operation of the hospital is very complex, many indicators are still bound to the use of innovative drugs for medical institutions. For example, the public hospital performance assessment (“national examination”) has an important assessment index is “medical service ratio” (medical service income ratio = medical service income / medical income × 100%), if the innovative drugs are included in the medical income, this index figure will inevitably decline.
MEDICAL WISDOM: What constitutes true innovation in the pharmaceutical field?
Jin Chunlin: It is very important to define “innovation”, which involves the implementation of relevant support policies. Pharmacovigilance pays more attention to pharmacology, taking new targets, mechanisms and structures as the basis for innovation, but health insurance, as a buyer, emphasizes clinical value, i.e., clinical safety and efficacy. For example, whether the drug can improve the survival rate, like whether the tumor treatment drug can prolong the progression-free survival period, etc., and pay more attention to the unmet clinical needs. The whole chain support policy for innovative drugs is an incentive policy from the perspective of health insurance.
MedJ : You have been a strong promoter of the concept of “value-based care”, how do you think this concept is reflected and applied in the support policy for the whole chain of innovative drugs?
Jin Chunlin: The core concept of value-based healthcare is the pursuit of cost-effective healthcare, that is, a higher input-output ratio embodied in the pharmaceutical industry end of the spectrum, that is, the pursuit of higher pharmaceutical output. In the real environment, there are too many me-too products in our country, and everyone is rolled up in the same target or pipeline. Therefore, on the policy end, we should encourage staggered competition and tilt towards truly innovative drugs. For example, in health insurance pricing, different payment standards can be drawn up according to the degree of innovation, so that companies will choose to take the initiative to take risks.
In order to discuss the significance of value-based medicine in the world and in contemporary China, “2024 Medical Value-Based Medicine Conference” will have a special sub-forum for the pharmaceutical industry, in which Director Jin Chunlin will share his views on the application of value-based medicine in the development of the whole chain of the biomedical industry. Please look forward to it!